Exagen (NASDAQ:XGN - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20), RTT News reports. The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. During the same quarter in the prior year, the firm earned ($0.19) EPS.
Exagen Price Performance
Exagen stock traded up $0.41 during trading hours on Wednesday, hitting $6.83. 699,725 shares of the company traded hands, compared to its average volume of 98,789. The firm's 50-day simple moving average is $4.43 and its two-hundred day simple moving average is $4.06. The firm has a market cap of $122.95 million, a P/E ratio of -7.27 and a beta of 1.50. Exagen has a 1-year low of $1.35 and a 1-year high of $7.20. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.
Analysts Set New Price Targets
Several equities research analysts have weighed in on XGN shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 target price on shares of Exagen in a research report on Monday, January 13th. BTIG Research reaffirmed a "buy" rating on shares of Exagen in a report on Wednesday. Finally, William Blair reissued an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th.
Check Out Our Latest Report on Exagen
Exagen Company Profile
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Featured Articles
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
